Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun;62(6):1490-1496.
doi: 10.1080/10428194.2021.1872070. Epub 2021 Jan 18.

Convalescent hyperimmune plasma for chemo-immunotherapy induced immunodeficiency in COVID-19 patients with hematological malignancies

Silvia Ferrari  1 , Chiara Caprioli  1 , Alessandra Weber  1 , Alessandro Rambaldi  1   2 , Federico Lussana  1
Affiliations

Convalescent hyperimmune plasma for chemo-immunotherapy induced immunodeficiency in COVID-19 patients with hematological malignancies

Silvia Ferrari et al. Leuk Lymphoma. 2021 Jun.

Abstract

During the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak, patients with defective immunity after chemo-immunotherapy due to hematological disorders showed prolonged symptoms and worse prognosis of coronavirus disease-2019 (COVID-19) pneumonia, probably due to inadequate adaptive immune response and noneffective viral clearance. We describe a single-center series of hematological immunocompromised patients undergoing passive immunization with hyperimmune plasma for persistent COVID-19 symptoms. In all cases, such treatment was well tolerated and contributed to clinical and radiological improvement and recovery; viral clearance was also achieved in a patients' subset. Although requiring further investigation, these results suggest a specific role for hyperimmune plasma administration in hematological patients.

Keywords: COVID-19; hyperimmune plasma; immunodeficiency; onco-hematological patients.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

Figures

Figure 1.
Figure 1.
Radiological improvement before and after infusion of hyperimmune plasma in patients 1 and 7.
Figure 2.
Figure 2.
Summary of clinical course by individual patients and radiological improvement before and after infusion of hyperimmune plasma in patients 1 (upper quadrant) and 7 (lower quadrant).
See this image and copyright information in PMC

Comment in

References

    1. Wu Z, McGoogan JM.. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in china: summary of a report of 72 314 cases from the chinese center for disease control and prevention. JAMA. 2020;323(13):1239–1242. - PubMed
    1. Mair-Jenkins J, Saavedra-Campos M, Baillie K JK , et al. ; Convalescent Plasma Study Group The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015;211(1):80–90. - PMC - PubMed
    1. Hui DS, Lee N, Chan PK, et al. . The role of adjuvant immunomodulatory agents for treatment of severe influenza. Antiviral Res. 2018;150:202–216. - PMC - PubMed
    1. Hung IFN, To KKW, Lee CK, et al. . Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Influenza A (H1N1) Infection. Chest. 2013;144(2):464–473. - PubMed
    1. Shen C, Wang Z, Zhao F, et al. . Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020;323(16):1582–1589. - PMC - PubMed

LinkOut - more resources